Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Expanded Access Program: TAK-755 (rADAMTS13) for the Prophylaxis and Treatment of Severe Congenital or Hereditary Thrombotic Thrombocytopenic Purpura
Sponsor: Takeda
A observational or N/A phase clinical study on Thrombotic Thrombocytopenic Purpura (TTP), this trial is ongoing. The trial is conducted by Takeda and has accumulated 5 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Mar 2025 — Present [monthly]
Approved For Marketing
Status: Available → Approved For Marketing
-
Sep 2024 — Mar 2025 [monthly]
Available
-
Jul 2024 — Sep 2024 [monthly]
Available
-
May 2023 — Jul 2024 [monthly]
Available
-
Apr 2023 — May 2023 [monthly]
Available
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.